Corpus ID: 23611441

Metabolic effects of acarbose in young healthy men.

  title={Metabolic effects of acarbose in young healthy men.},
  author={Charles Couet and Matthias Ulmer and Mohammed Seddik Hamdaoui and Hwei Ming Bau and G{\'e}rard Debry},
  journal={European journal of clinical nutrition},
  volume={43 3},
To explore the long-term metabolic effects of acarbose in man, 6 healthy men (25 +/- 2 years; BMI: 21.6 +/- 2.7) were fed a controlled diet in a metabolic ward for 7 consecutive weeks. After an initial 3-week period to ensure a metabolic steady-state, they received 300 mg/d of acarbose (100 mg before each meal) for the remaining 4 weeks. Stool and urine collections were made over 7 d on weeks 3 and 7. Faecal excretion of water, nitrogen, carbohydrate, fat, zinc, magnesium, copper, chromium… Expand
Acarbose treatment in obesity: a controlled study
Additional acarbose therapy is not more beneficial than low-calorie diet therapy alone, and body weight, BM and skinfold thickness decreased significantly in both groups. Expand
Comparison of Acarbose and Gliclazide as First-line Agents in Patients with Type 2 Diabetes
It is demonstrated that acarbose and gliclazide were reasonably effective in improving metabolic control in patients insufficiently controlled with diet alone, and both treatments were well tolerated. Expand
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
Both drugs were effective in reducing of HbA1C, fasting and PP blood glucose levels, and the effect of treatment was evaluated by fasting and postprandial metabolic parameters, Hb a1C and plasma lipid levels. Expand
Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance
Acarbose has a positive therapeutic effect on glucose tolerance in cystic fibrosis patients, as shown by attenuation of postprandial plasma glucose increase and a significant decrease in insulin secretion response, however, acarbose treatment was associated with adverse gastro-intestinal effects that may prevent patients from accepting long-term therapy. Expand
A Risk-Benefit Appraisal of Acarbose in the Management of Non-Insulin-Dependent Diabetes Mellitus
In conclusion, acarbose may be useful in patients with NIDDM when diet alone is no longer able to maintain satisfactory blood glucose control, and may be a valid alternative to sulphonylurea or biguanide therapy when these drugs are contraindicated and insulin administration may be delayed. Expand
Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia
Reduction of hyperinsulinaemia appears to be the mechanism by which acarbose treatment can improve plasma lipid concentrations. Expand
A Review of the Safety and Efficacy of Acarbose in Diabetes Mellitus
Potential advantages of acarbose include a greater effectiveness in controlling postprandial hyperglycemia, a low risk of hypoglyceemia, and a possible delay in initiating insulin therapy. Expand
Erratum to Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus
Clinical trials have demonstrated that acarbose generally improves glycaemic control in patients with non-insulin-dependent diabetes mellitus managed with diet alone, or with other antidiabetic therapy, as evidenced by decreased postprandial plasma glucose and glycosylated haemoglobin levels. Expand
Safety Profile of Acarbose, an α-Glucosidase Inhibitor
Almost all adverse experiences of acarbose were related to the digestive system and included diarrhoea, flatulence, bloating and nausea, and the adverse experience profile was clinically acceptable. Expand
Acarbose: An update of its therapeutic use in diabetes treatment
Acarbose is a first-line treatment for newly diagnosed patients with type 2 diabetes, those who have high postprandial blood glucose and for patients where dietary treatment alone provides inadequate glycaemic control. Expand